What is Certara?
Certara is a comprehensive drug development company that provides a suite of services and software solutions designed to support the entire drug lifecycle, from initial discovery through to market access. Headquartered in Princeton, NJ, with a global presence, Certara empowers pharmaceutical and biotechnology companies to accelerate the development of novel therapies. Its offerings encompass regulatory consulting, clinical trial optimization, evidence generation, and market access strategies, positioning it as a critical partner in bringing life-changing medicines to patients.
How much funding has Certara raised?
Certara has raised a total of $1.4B across 3 funding rounds:
Stock Offering
$668M
Stock Offering
$310M
Private Equity
$449M
Stock Issuance/Offering (2020): $668M with participation from Undisclosed
Stock Issuance/Offering (2021): $310M, investors not publicly disclosed
Private Equity (2022): $449M supported by Arsenal Capital Partners
Key Investors in Certara
Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity firm specialized in investments in middle-market industrial growth and healthcare companies. Since its inception in 2000, the firm has distinguished itself through a "build-for-tomorrow" philosophy, focusing on high-growth, technology-, and innovation-rich businesses that are strategically important to their respective markets. Arsenals investment strategy is deeply rooted in sector expertise; the firm employs a team of nearly 100 professionals that includes seasoned industry executives, scientists, and technical experts. This allows the firm to partner effectively with management teams to execute multi-faceted growth strategies, often involving complex buy-and-build models.
What's next for Certara?
With substantial backing, Certara is strategically positioned for accelerated growth and further enhancement of its service and software portfolio. The recent major strategic investment signals a focus on expanding its global reach, investing in advanced technological capabilities, and potentially pursuing strategic acquisitions to broaden its service offerings. This capital will likely fuel innovation in areas such as real-world evidence generation and advanced analytics, reinforcing Certara's leadership in supporting the complex journey of drug development and commercialization.
See full Certara company page
